Company news

Edgewise Therapeutics, Inc. news in 2024

Edgewise Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

December 15, 2024

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

December 4, 2024

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

November 25, 2024

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 6, 2024

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

September 30, 2024

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

September 18, 2024

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8: 30 am Eastern Time

September 16, 2024

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 7, 2024

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

May 9, 2024

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

May 6, 2024

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

May 5, 2024

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

April 22, 2024

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

April 14, 2024

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

March 27, 2024

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

March 26, 2024

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

March 4, 2024

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

February 27, 2024

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 21, 2024

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

February 12, 2024

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

January 18, 2024

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

January 8, 2024

Decks in 2024